ARWR
Time to buy ARWR?$73.50
$-5.55 (-7.02%)
2 Days. Real Options Skills.
Join options trader Ben Sturgill as he reveals his most reliable options strategies - live. Seats are limited.
Save your seatTrader's Perspective
ARWR ran from roughly $64 in early January to a recent high near $82 in May as commercial traction for REDEMPLO and fresh obesity and cardiometabolic trial data kept the bid alive.
A failure to hold $73 could see a retrace toward the $68 to $70 range. Any slowdown in REDEMPLO uptake, or fresh pressure from the January 2026 stock and convertible note financing overhang, would accelerate the downside.
If ARWR holds the $73 to $75 area, a move back toward $80 to $82 is on the table. Resistance at $78 is the first hurdle, and more upside could come if commercial prescription growth or new pipeline data stay strong.
Analyst Ratings
Arrowhead Pharmaceuticals Inc. Earnings
We don't currently have information about Arrowhead Pharmaceuticals Inc.'s earnings.